Additionally, among the 53 drugs approved based on a new mechanism of action, regardless of the tumor type, 50 distinct biological targets were identified, with 4 having already approved drugs before 2009 (ERBB2, CD20, the cell cycle for chemotherapy, and vascular endothelial growth factor [VEGF]). This evidence concerns the gene ERBB2 and neoplasm.